The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NRXP | +109.52% | -97.54% | -52.35% | -97% |
| S&P | +14.49% | +91.09% | +13.83% | +160% |
NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.
Investors are intrigued by the potential of the drugmaker's experimental coronavirus therapy.
The company received good news from the FDA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 100.0% |
| Market Cap | $63.58M | 172.3% |
| Net Income | -$17.58M | -122.6% |
| EBITDA | -$3.73M | 47.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.91M | 53.3% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $10.23M | 19.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -669.06% | -471.1% |
| Return On Invested Capital | -64.23% | 27.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4.03M | -14.9% |
| Operating Free Cash Flow | -$4.03M | -14.9% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -0.99 | -1.33 | -1.29 | -2.22 | 40.18% |
| Price to Tangible Book Value | -0.99 | -1.33 | -1.29 | -2.22 | 40.18% |
| Enterprise Value to EBITDA | -7.80 | -8.53 | -9.74 | -17.64 | 284.21% |
| Total Debt | $6.67M | $6.58M | $8.40M | $10.23M | 19.06% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
